Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 476 - 500 of 11968 in total
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Approved
Matched Description: … A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and …
Pholcodine formula is 3-o-morpholinoethylmorphine and it is classified as an antitussive which is defined as an opioid cough suppressant. It belongs to the opioid family of compounds and it is widely used. Pholcodine activity is the suppression of unproductive cough and it also has a mild sedative effect with little...
Approved
Illicit
Matched Iupac: … (1S,5R,13R,14S,17R)-4-methyl-10-[2-(morpholin-4-yl)ethoxy]-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17 …
The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). As of November 2022, it is the primary circulating variant of...
Approved
Investigational
Matched Description: … The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. ... [L43917] Famtozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant ... administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, …
Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine...
Approved
Investigational
Matched Iupac: … -trioxa-20,36,39,53,55,58-hexaazaundecacyclo[38.14.2.2^{3,6}.2^{14,17}.2^{19,34}.1^{8,12}.1^{23,27}.1 ... yl]oxy}-2-{[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-26,31,44,49-tetrahydroxy ... ,52S)-22-amino-5,63-dichloro-64-{[(2S,3R,4R,5S,6R)-3-decanamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2- ... -21,35,38,54,56,59-hexaoxo-47-{[(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-7,13,28 …
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval...
Approved
Investigational
Matched Description: … [L2933] The treatment effect was maintained for up to 12 months.[L2933] …
Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939.
Approved
Matched Iupac: … 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol …
Matched Mixtures name: … Ryna -12 ... Ryna -12 S ... AFRINEX EFX 12
Matched Products: … Green Guard Allergy 2 Relief …
Vasomotor symptoms (VMS), more colloquially known as hot flashes or night sweats, are some of the most common symptoms in menopause. With a median duration of 7.4 years, vasomotor symptoms are also the most common reasons why women seek treatments for menopausal issues.[A259591,A259596] Although mostly considered a nuisance, vasomotor symptoms...
Approved
Investigational
Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About...
Approved
Investigational
Matched Description: … Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2
Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under...
Approved
Illicit
Investigational
Matched Iupac: … (1S,5R,13R,14S,17R)-10-(acetyloxy)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca …
Indocyanine Green is a water soluble, tricarbocyanine dye with a peak spectral absorption at 800 nm. The chemical name for Indocyanine Green is 1 H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e] indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-,hydroxide, inner salt, sodium salt. Indocyanine Green for Injection USP has a pH of approximately 6.5 when reconstituted. Each vial of Indocyanine Green for...
Approved
Investigational
Matched Iupac: … 2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-1H,2H,3H-benzo[e]indol-2-ylidene]hepta-1,3,5-trien-1-yl}-1,1-dimethyl …
Matched Description: … )-2H-benz[e] indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-,hydroxide, inner salt ... The chemical name for Indocyanine Green is 1 H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Iodine is commonly used as an antiseptic for minor cuts and abrasions, preventing infections that may result from contaminated wounds. Additionally, iodine has been studied in the treatment of fibrocystic disease and breast cancer.[A3413,A192153,A192156,A192159]
Approved
Investigational
Matched Mixtures name: … For-2 ... Iodine Tincture 21/2% ... GNP Idoinde Tincture 2% Mild …
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Approved
Investigational
Withdrawn
Matched Categories: … COX-2 Inhibitors ... Selective Cyclooxygenase 2 Inhibitors (NSAIDs) …
Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m2. Its potency in inhibiting SGLT2 is similar...
Approved
Investigational
Matched Iupac: … (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(methylsulfanyl)oxane-3,4,5-triol …
Matched Description: … to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m2< …
Matched Categories: … Sodium-Glucose Transporter 2 Inhibitors ... Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors …
Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
Approved
Investigational
Matched Iupac: … (4S)-4-{[(2S)-2-{[(2S)-2-amino-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene]amino}-3-carboxy-1-hydroxypropylidene ... ,7S,10S,13S,16R,19S,22S,25R,32S,38R)-38-{[(1S)-1-carboxy-3-methylbutyl]-C-hydroxycarbonimidoyl}-22-(2- ... methylpropyl)-7,13-bis(propan-2-yl)-27,28,40,41-tetrathia-2,5,8,11,14,17,20,23,31,34,37-undecaazabicyclo ... 3,6,9,12,15,18,21,24,30,33,36-undecahydroxy-10-[(C-hydroxycarbonimidoyl)methyl]-32-[(1R)-1-hydroxyethyl]-4-methyl-19-(2- …
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Approved
Matched Iupac: … 1,3-bis[(4-phenylbutanoyl)oxy]propan-2-yl 4-phenylbutanoate …
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 . It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for...
Approved
Matched Iupac: … ]oxy}-2-ethyl-3,4,10-trihydroxy-13-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,6,8,10,12,14 ... (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl …
Matched Products: … ZITROTEK FILM KAPLI TABLET, 2 ADET ... AZİTROTEK 500 MG FİLM TABLET, 2 TABLET ... ZITROMAX SD 2 G/60 ML ORAL SÜSPANSIYON IÇIN UZATILMIŞ SALIMLI GRANÜL …
Ferric subsulfate is a stypic or hemostatic agent that causes agglutination of surface proteins resulting in local hemostasis. It has the chemical formula Fe4(OH)2(SO4)5. It is used after superficial skin biopsies.
Approved
Experimental
Matched Description: … It has the chemical formula Fe4(OH)2(SO4)5. It is used after superficial skin biopsies. …
Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically...
Approved
Investigational
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation....
Approved
Investigational
Matched Iupac: … N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only...
Approved
Investigational
Matched Description: … It is composed of 2 heavy chains, each containing 456 amino acids, and 2 light chains of the lambda subclass …
Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.
Approved
Matched Iupac: … N''-({1,4-dioxaspiro[4.5]decan-2-yl}methyl)guanidine …
Matched Salts cas: … 22195-34-2
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class...
Approved
Investigational
Approved
Experimental
Matched Iupac: … trimanganese(2+) bis(2-hydroxypropane-1,2,3-tricarboxylate) …
Matched Mixtures name: … Tricare Prenatal 2-part Daily Prenatal Vitamin System …
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of...
Approved
Investigational
Matched Iupac: … (1S,2R,18R,19R,22S,25R,28R,40S)-2-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy}-22-(carbamoylmethyl ... yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-18,32,35,37-tetrahydroxy-19-[(2R)-4-methyl-2-(methylamino ... ,6R)-3-{[(2S,4S,5R,6S)-4-[({4'-chloro-[1,1'-biphenyl]-4-yl}methyl)amino]-5-hydroxy-4,6-dimethyloxan-2- ... )pentanamido]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2^{3,6}.2^{ …
Matched Description: … [A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in …
Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets . The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved...
Approved
Investigational
Displaying drugs 476 - 500 of 11968 in total